» Articles » PMID: 31371206

The Global Burden of Childhood and Adolescent Cancer in 2017: an Analysis of the Global Burden of Disease Study 2017

Overview
Journal Lancet Oncol
Specialty Oncology
Date 2019 Aug 3
PMID 31371206
Citations 140
Affiliations
Soon will be listed here.
Abstract

Background: Accurate childhood cancer burden data are crucial for resource planning and health policy prioritisation. Model-based estimates are necessary because cancer surveillance data are scarce or non-existent in many countries. Although global incidence and mortality estimates are available, there are no previous analyses of the global burden of childhood cancer represented in disability-adjusted life-years (DALYs).

Methods: Using the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 methodology, childhood (ages 0-19 years) cancer mortality was estimated by use of vital registration system data, verbal autopsy data, and population-based cancer registry incidence data, which were transformed to mortality estimates through modelled mortality-to-incidence ratios (MIRs). Childhood cancer incidence was estimated using the mortality estimates and corresponding MIRs. Prevalence estimates were calculated by using MIR to model survival and multiplied by disability weights to obtain years lived with disability (YLDs). Years of life lost (YLLs) were calculated by multiplying age-specific cancer deaths by the difference between the age of death and a reference life expectancy. DALYs were calculated as the sum of YLLs and YLDs. Final point estimates are reported with 95% uncertainty intervals.

Findings: Globally, in 2017, there were 11·5 million (95% uncertainty interval 10·6-12·3) DALYs due to childhood cancer, 97·3% (97·3-97·3) of which were attributable to YLLs and 2·7% (2·7-2·7) of which were attributable to YLDs. Childhood cancer was the sixth leading cause of total cancer burden globally and the ninth leading cause of childhood disease burden globally. 82·2% (82·1-82·2) of global childhood cancer DALYs occurred in low, low-middle, or middle Socio-demographic Index locations, whereas 50·3% (50·3-50·3) of adult cancer DALYs occurred in these same locations. Cancers that are uncategorised in the current GBD framework comprised 26·5% (26·5-26·5) of global childhood cancer DALYs.

Interpretation: The GBD 2017 results call attention to the substantial burden of childhood cancer globally, which disproportionately affects populations in resource-limited settings. The use of DALY-based estimates is crucial in demonstrating that childhood cancer burden represents an important global cancer and child health concern.

Funding: Bill & Melinda Gates Foundation, American Lebanese Syrian Associated Charities (ALSAC), and St. Baldrick's Foundation.

Citing Articles

Childhood Cancer Survivorship Care in Limited Resource Settings: A Narrative Review and Strategies to Promote Global Health Equity.

Noyd D, Izurieta-Pacheco A, Mzikamanda R, Nakiddu N, An D, Souvanlasy B JCO Glob Oncol. 2025; 11:e2400274.

PMID: 39946668 PMC: 11892615. DOI: 10.1200/GO-24-00274.


Addressing the Alarming Rise in Pediatric Cancer Prevalence in India: A Call to Action.

Pathan S, Bhende V, Sharma K, Chowdappa R, Patel V, Gangoda D Health Sci Rep. 2025; 8(2):e70429.

PMID: 39931262 PMC: 11808317. DOI: 10.1002/hsr2.70429.


Exploring experiences and needs among children with cancer undergoing peripherally inserted central catheter insertion: A qualitative study.

Li C, Wang C, Zhuang X, Wang Y, Wu Y, Hu R Asia Pac J Oncol Nurs. 2025; 12:100654.

PMID: 39917032 PMC: 11800096. DOI: 10.1016/j.apjon.2025.100654.


Availability and accessibility of cytotoxic medicines in the WHO model list of essential medicines for childhood cancer in low and lower-middle- income countries: a systematic review.

Seneviwickrama M, Denagamagei S, Jayakody S, Gunasekera S, Liyanage G BMC Cancer. 2025; 25(1):181.

PMID: 39891074 PMC: 11783793. DOI: 10.1186/s12885-025-13586-2.


Cognitive-Behavioral Intervention for Children With Hematological Cancer Receiving Chemotherapy: A Randomized Controlled Trial.

Melesse T, Li W, Chun Chau J, Yimer M, Gidey A, Yitayih S Psychooncology. 2025; 34(1):e70086.

PMID: 39828642 PMC: 11743426. DOI: 10.1002/pon.70086.


References
1.
. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1736-1788. PMC: 6227606. DOI: 10.1016/S0140-6736(18)32203-7. View

2.
Ward Z, Yeh J, Bhakta N, Frazier A, Atun R . Estimating the total incidence of global childhood cancer: a simulation-based analysis. Lancet Oncol. 2019; 20(4):483-493. DOI: 10.1016/S1470-2045(18)30909-4. View

3.
Friedrich P, Lam C, Itriago E, Perez R, Ribeiro R, Arora R . Magnitude of Treatment Abandonment in Childhood Cancer. PLoS One. 2015; 10(9):e0135230. PMC: 4589240. DOI: 10.1371/journal.pone.0135230. View

4.
. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1789-1858. PMC: 6227754. DOI: 10.1016/S0140-6736(18)32279-7. View

5.
Gupta S, Aitken J, Bartels U, Brierley J, Dolendo M, Friedrich P . Paediatric cancer stage in population-based cancer registries: the Toronto consensus principles and guidelines. Lancet Oncol. 2016; 17(4):e163-e172. DOI: 10.1016/S1470-2045(15)00539-2. View